Latest Data on Suspected Adverse Events with COVID-19 Vaccines

Dawn O'Shea

November 15, 2021

The number of suspected adverse events (AEs) reported in the European Union/European Economic Area (EU/EEA) up to the end of October stands at 749,979 out of almost 575 million doses, according to the latest data from the European Medicines Agency (EMA). The figure suggests a rate of 1.3%, although this may not reflect the true prevalence as the reports related to suspected AEs, and there is also the likelihood that mild AEs may not have been reported.

The incidence of possible AEs with each vaccine range from 0.96% per dose for Comirnaty (PfizerBioNTech), 0.3% with Vaxzevria (AstraZeneca), 0.17% with the Janssen vaccine and 0.15% with Spikevax (Moderna).

A possible link between Comirnaty and Spikevac with myocarditis/pericarditis is still being reviewed. Furthermore, the agency said there is currently insufficient evidence to confirm or rule out a link with multisystem inflammatory syndrome (MIS) with all four vaccines.

It has also been concluded that there is insufficient evidence to support a possible causal relationship between the Janssen vaccine and menstrual disorders. As of 30 September 2021, 1238 cases of menstrual disorders had been reported worldwide following receipt of the vaccine. Of these, 550 were received during the previous monthly reporting period.

This article originally appeared on Univadis, part of the Medscape Professional Network.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.